⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676147 | 0.76 | CYP2A6 (0.37) | — | |
| SCHEMBL4769454 | 0.74 | POLB (0.34) | — | |
| SCHEMBL13902223 | 0.74 | — | — | |
| SCHEMBL2243607 | 0.74 | — | — | |
| SCHEMBL2302986 | 0.72 | — | — | |
| SCHEMBL7368557 | 0.70 | — | — | |
| SCHEMBL4550191 | 0.70 | — | — | |
| SCHEMBL13058962 | 0.70 | — | — | |
| SCHEMBL4087110 | 0.70 | — | — | |
| SCHEMBL8559824 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| US-11667630-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2023-06-06 | — | — | US | disclosed |
| CN-111511736-B | Nitrogen-containing 6-membered ring compound | 旭化成制药株式会社 | 2023-03-24 | — | — | CN | disclosed |
| EP-3733665-B1 | 2-OXO-1,3,4-THIADIAZINAN-3-YL MOIETY CONTAINING COMPOUNDS WITH EP4 RECEPTOR AGONIST ACTIVITY | ASAHI KASEI PHARMA CORP (JP) | 2022-09-28 | — | — | EP | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-20210188837-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-10988468-B2 | Nitrogen-containing 6-membered cyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2021-04-27 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| US-20200347046-A1 | NITROGEN-CONTAINING 6-MEMBERED CYCLIC COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
| CN-1367785-A | Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing substituted phenylenediamine groups | AMERICAN HOME PROD (US) | 2002-09-04 | — | — | CN | disclosed |
| CN-1348446-A | Heterocyclic carboxamide-containing thiourea inhibitors of herpes viruses containing phenylenediamine groups | AMERICAN HOME PROD (US) | 2002-05-08 | — | — | CN | disclosed |
| CN-1335843-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-02-13 | — | — | CN | disclosed |
| CN-1333750-A | Acetamide and substituted acetamide-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1333769-A | Thiourea inhibitors of herps viruses | AMERICAN HOME PROD (US) | 2002-01-30 | — | — | CN | disclosed |
| CN-1332725-A | Thiourea inhibitors of herpes viruses | AMERICAN HOME PROD (US) | 2002-01-23 | — | — | CN | disclosed |